Boston Scientific is pleased to announce the approval of the new Sacral Neuromodulation External Trial System (ETS-02). Product availability reflects FDA approval and our continued commitment to patient and clinician centric product solutions.

The External Trial System (ETS-02) builds upon the previous External Trial System platform to support physicians in the treatment of incontinence. The system is used during a temporary evaluation period to determine if a patient will respond to the Boston Scientific sacral neuromodulation system. The new External Trial Stimulator and dressing enable patients to shower during the basic trial.

This release does not change the intended use of the device and maintains alignment with existing clinical applications for sacral neuromodulation procedures.

Boston Scientific remains committed to advancing technologies that support physicians and improve patient care. The introduction of the External Trial System (ETS-02) reflects our ongoing investment in delivering meaningful innovation across our urology portfolio.

Availability of the External Trial System (ETS-02) in the United States will begin in the coming months. For additional information, please contact your Boston Scientific sales representative.

Thank you for your continued support and confidence in Boston Scientific.
Together, we are advancing science for life.

Best,

Boston Scientific Urology

Axonics SNM System Brief Summary
Indications, Safety, and Warnings – Boston Scientific

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician. URO-2535309-AB JUL 2026